Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2

Due to the COVID-19 pandemic, the rapid development of vaccines against SARS-CoV-2 has been promoted. BNT162b2 is a lipid-nanoparticle mRNA vaccine with 95% efficacy and is the most administered vaccine globally. Nevertheless, little is known about the cellular immune response triggered by vaccinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Vega-Magaña, Natali, Muñoz-Valle, José Francisco, Peña-Rodríguez, Marcela, Viera-Segura, Oliver, Pereira-Suárez, Ana Laura, Hernández-Bello, Jorge, García-Chagollan, Mariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319730/
https://www.ncbi.nlm.nih.gov/pubmed/35891281
http://dx.doi.org/10.3390/vaccines10071117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319730/
https://www.ncbi.nlm.nih.gov/pubmed/35891281
http://dx.doi.org/10.3390/vaccines10071117

Ejemplares similares